Cargando…

Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence

Mostrar otras versiones (1)

BACKGROUND: Novel immunotherapy combination therapies have improved outcomes for patients with hepatocellular carcinoma (HCC), but responses are limited to a subset of patients. Little is known about the inter- and intra-tumor heterogeneity in cellular signaling networks within the HCC tumor microen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Shuming, Yuan, Long, Danilova, Ludmila, Mo, Guanglan, Zhu, Qingfeng, Deshpande, Atul, Bell, Alexander T. F., Elisseeff, Jennifer, Popel, Aleksander S., Anders, Robert A., Jaffee, Elizabeth M., Yarchoan, Mark, Fertig, Elana J., Kagohara, Luciane T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10506285/ https://www.ncbi.nlm.nih.gov/pubmed/37723590 http://dx.doi.org/10.1186/s13073-023-01218-y

Ejemplares similares

Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence
por: Zhang, Shuming, et al.
Publicado: (2023)

Informing virtual clinical trials of hepatocellular carcinoma with spatial multi-omics analysis of a human neoadjuvant immunotherapy clinical trial
por: Zhang, Shuming, et al.
Publicado: (2023)

Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity
por: Ho, Won Jin, et al.
Publicado: (2021)

Multi-Scale Spatial Analysis of the Tumor Microenvironment Reveals Features of Cabozantinib and Nivolumab Efficacy in Hepatocellular Carcinoma
por: Mi, Haoyang, et al.
Publicado: (2022)

Integrated immunological analysis of a successful conversion of locally advanced hepatocellular carcinoma to resectability with neoadjuvant therapy
por: Ho, Won Jin, et al.
Publicado: (2020)

Mechanistically detailed systems biology modeling of the HGF/Met pathway in hepatocellular carcinoma
por: Jafarnejad, Mohammad, et al.
Publicado: (2019)

Integrating single cell sequencing with a spatial quantitative systems pharmacology model spQSP for personalized prediction of triple-negative breast cancer immunotherapy response
por: Zhang, Shuming, et al.
Publicado: (2021)

Immune landscape of tertiary lymphoid structures in hepatocellular carcinoma (HCC) treated with neoadjuvant immune checkpoint blockade
por: Shu, Daniel H., et al.
Publicado: (2023)

Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma
por: Ho, Won Jin, et al.
Publicado: (2020)

Analysis of gene expression of secreted factors associated with breast cancer metastases in breast cancer subtypes
por: Fertig, Elana J., et al.
Publicado: (2015)

Epigenetic regulation of gene expression in cancer: techniques, resources and analysis
por: Kagohara, Luciane T, et al.
Publicado: (2017)

Cabozantinib/ipilimumab/nivolumab interaction: Haemophagocytic lymphohistiocytosis: case report
Publicado: (2021)

Integrated T cell cytometry metrics for immune-monitoring applications in immunotherapy clinical trials
por: Sidiropoulos, Dimitrios N., et al.
Publicado: (2022)

Extracellular Vesicles Released by Tumor Endothelial Cells Spread Immunosuppressive and Transforming Signals Through Various Recipient Cells
por: Lopatina, Tatiana, et al.
Publicado: (2020)

Cabozantinib‐nivolumab sequence in metastatic renal cell carcinoma: The CABIR study
por: Vano, Yann‐Alexandre, et al.
Publicado: (2022)

Transfer learning between preclinical models and human tumors identifies a conserved NK cell activation signature in anti-CTLA-4 responsive tumors
por: Davis-Marcisak, Emily F., et al.
Publicado: (2021)

Hybrid Modeling of Cell Signaling and Transcriptional Reprogramming and Its Application in C. elegans Development
por: Fertig, Elana J., et al.
Publicado: (2011)

Generating colorblind-friendly scatter plots for single-cell data
por: Guha, Tejas, et al.
Publicado: (2022)

Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy
por: Li, Keyu, et al.
Publicado: (2022)

Digital Pathology Analysis Quantifies Spatial Heterogeneity of CD3, CD4, CD8, CD20, and FoxP3 Immune Markers in Triple-Negative Breast Cancer
por: Mi, Haoyang, et al.
Publicado: (2020)

Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma
por: Wiecek, Witold, et al.
Publicado: (2016)

Breast cancer cells condition lymphatic endothelial cells within pre-metastatic niches to promote metastasis
por: Lee, Esak, et al.
Publicado: (2014)

Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China
por: Wang, Hao, et al.
Publicado: (2022)

Integrated time course omics analysis distinguishes immediate therapeutic response from acquired resistance
por: Stein-O’Brien, Genevieve, et al.
Publicado: (2018)

Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA
por: Izumchenko, Evgeny, et al.
Publicado: (2015)

Integrated single-cell and bulk gene expression and ATAC-seq reveals heterogeneity and early changes in pathways associated with resistance to cetuximab in HNSCC-sensitive cell lines
por: Kagohara, Luciane T., et al.
Publicado: (2020)

Correction: Integrated single-cell and bulk gene expression and ATAC-seq reveals heterogeneity and early changes in pathways associated with resistance to cetuximab in HNSCC-sensitive cell lines
por: Kagohara, Luciane T., et al.
Publicado: (2020)

Neoadjuvant nivolumab and cabozantinib in advanced renal cell carcinoma in a horseshoe kidney – how to achieve a safe and radical resection? a case report and review of the literature
por: Zemankova, Anezka, et al.
Publicado: (2023)

Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study
por: Barroso-Sousa, Romualdo, et al.
Publicado: (2021)

Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer
por: Lheureux, Stephanie, et al.
Publicado: (2022)

Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma
por: Tran, Benjamin Duy, et al.
Publicado: (2023)

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
por: Apolo, Andrea B., et al.
Publicado: (2020)

BONSAI-2 study: Nivolumab as therapeutic option after cabozantinib failure in metastatic collecting duct carcinoma patients
por: Buti, Sebastiano, et al.
Publicado: (2022)

Neoadjuvant relatlimab and nivolumab in resectable melanoma
por: Amaria, Rodabe N., et al.
Publicado: (2022)

Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways
por: Ho, Won Jin, et al.
Publicado: (2021)

Case Report: Exceptional response to nivolumab plus cabozantinib in a patient with extrarenal clear cell renal cell carcinoma
por: Jansen, Caroline S., et al.
Publicado: (2023)

Complete response of metastatic papillary renal cell carcinoma with inferior vena cava tumor thrombus to nivolumab plus cabozantinib
por: Hayashida, Michikata, et al.
Publicado: (2023)

A Random Forest Genomic Classifier for Tumor Agnostic Prediction of Response to Anti-PD1 Immunotherapy
por: Bigelow, Emma, et al.
Publicado: (2022)

A Durable Response With the Combination of Nivolumab and Cabozantinib in a Patient With Metastatic Paraganglioma: A Case Report and Review of the Current Literature
por: Economides, Minas P., et al.
Publicado: (2020)

Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy
por: Girardi, Daniel M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_iph8u9425bb11trba4ujdhcp05